SIRION Biotech presents at SACHS Forum in Zurich

Investment opportunities with viral vector technologies

Martinsried, (PresseBox) - SACHS Associates is holding its 7th Annual European Life Science CEO Forum for Partnering & Investing at the Zurich airport. SIRION Biotech is to present investment opportunities with viral vectors for gene studies, gene therapy and vaccines.

Website Promotion

SIRION BIOTECH GmbH

SIRION Biotech started in Munich in 2007 with the idea of enabling novel cell models closer to reality than ever before. This required the assembly of an all-encompassing, novel viral vector platform. Both, designing de novo viral vectors and the subsequent creation of custom cell models will pave the way for superior compound development in the life sciences. SIRION's technologies have been validated in over 300 single projects with more than 100 academic and industrial partners. As a result, cell models for drug discovery and development have become highly reliable, as have the use of new viral vectors in gene therapy and vaccine studies.

www.SIRION-Biotech.com

Press releases you might also be interested in

Subscribe for news

The subscribtion service of the PresseBox informs you about press information of a certain topic by your choice at a choosen time. Please enter your email address to receive the email with the press releases.

An error occurred!

Thank you! You will receive a confirmation email within a few minutes.


I want to subscribe to the gratis press mail and have read and accepted the conditions.